Efficacy and safety of once-weekly oral trelagliptin switched from once-daily dipeptidyl peptidase-4 inhibitor in patients with type 2 diabetes mellitus: An open-label, phase 3 exploratory study-Reference-Cited by-同舟云学术

Efficacy and safety of once-weekly oral trelagliptin switched from once-daily dipeptidyl peptidase-4 inhibitor in patients with type 2 diabetes mellitus: An open-label, phase 3 exploratory study

Published:2017-10-30 Issue:2 Volume:9 Page:354-359
ISSN:2040-1116
Container-title:Journal of Diabetes Investigation
language:en
Short-container-title:J Diabetes Investig

Author:

Inagaki Nobuya¹^ORCID,Sano Hiroki²,Seki Yoshifumi²,Kuroda Shingo²,Kaku Kohei³

Affiliation:

1. Department of Diabetes, Endocrinology and Nutrition; Kyoto University Graduate School of Medicine; Kyoto Japan

2. Takeda Development Center Japan; Takeda Pharmaceutical Company Limited; Osaka Japan

3. Department of Internal Medicine; Kawasaki Medical School; Okayama Japan

Funder

Takeda Pharmaceutical Company

WysiWyg Co., Ltd.

Publisher

Wiley

Subject

General Medicine,Endocrinology, Diabetes and Metabolism,Internal Medicine

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/jdi.12730/fullpdf

Reference19 articles.

1. Treatment adherence in chronic disease;Dunbar-Jacob;J Clin Epidemiol,2001

2. Interventions for enhancing medication adherence;Haynes;Cochrane Database Syst Rev,2008

3. Clinical outcomes and adherence to medications measured by claims data in patients with diabetes;Pladevall;Diabetes Care,2004

4. A systematic review of adherence with medications for diabetes;Cramer;Diabetes Care,2004

5. Variations in patients’ adherence to medical recommendations: a quantitative review of 50 years of research;DiMatteo;Med Care,2004

Cited by 11 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The Structure-property Relationships of Clinically Approved Protease Inhibitors;Current Medicinal Chemistry;2024-04

2. Cellular and molecular mechanisms of the antidiabetic drugs under clinical trials;Biochemical Immunology of Diabetes and Associated Complications;2024

3. Prediction of pharmacokinetics and pharmacodynamics of trelagliptin and omarigliptin in healthy humans and in patients with renal impairment using physiologically based pharmacokinetic combined DPP-4 occupancy modeling;Biomedicine & Pharmacotherapy;2022-09

4. Safety and efficacy of once weekly dipeptidyl-peptidase-4 inhibitor trelagliptin in type-2 diabetes: A meta-analysis;Diabetes & Metabolic Syndrome: Clinical Research & Reviews;2022-04

5. Effects of the Once-Weekly DPP4 Inhibitor Omarigliptin on Glycemic Control in Patients with Type 2 Diabetes Mellitus on Maintenance Hemodialysis: A 24-Week Open-Label, Multicenter Randomized Controlled Study;Diabetes Therapy;2021-01-20